Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Approves Feasibility Trial Of Disappearing Tissue Tricuspid Valve

This article was originally published in The Gray Sheet

Executive Summary

CorMatrix Cardiovascular’s CorMatrix ECM tricuspid heart valve is a flexible, unstented valve that works as a replacement valve while also providing the scaffold on which the patient’s own tissue can form a new valve.

You may also be interested in...



New Products In Brief

CorMatrix Cardiovascular’s ECM

Upgraded Paige Suite Gains CE-IVD and UKCA Marks

Paige’s AI has obtained CE-IVD and UKCA marks, allowing the launch of a breakthrough product that can spot biomarkers from images.

Sanofi Scores In Second-Line Myeloma But Still In Darzalex’s Shadow

The French company believes it has the best-in-class CD38 antibody with new PFS data, but Johnson & Johnson and Genmab’s Darzalex looks set to retain its advantage in multiple myeloma.

Related Companies

UsernamePublicRestriction

Register

MT033698

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel